Charles Spivey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles Spivey has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alban Gaultier
Department of Neuroscience University of Virginia School of Medicine Charlottesville Virginia USA
1 shared publication - Anthony Fernández-Castañeda
Center for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication - Dorian A. Rosen
Center for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication - Kacper Posyniak
Center for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication - Ku-Lung Hsu
University of Texas at Austin
1 shared publication - Lelisa F. Gemta
Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication
Latest Publications
- 27 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (655)
Modulation of PKM activity affects the differentiation of T H 17 cells
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell–mediated autoimmunity that mimics multiple sclerosis (MS). TH17 cells are believed to orchestrate MS pathology, in part, through the production of two proinflammatory cytokines: interleukin-17 (IL-17) and GM-CSF. We found that both TEPP-46 and DASA-58 suppressed the development of IL-17–producing TH17 cells but increased the generation of those producing GM-CSF. This switch redirected disease pathology from the spinal cord to the brain. In addition, we found that activation of PKM2 interfered with TGF-β1 signaling, which is necessary for the development of TH17 and regulatory T cells. Collectively, our data clarify the therapeutic potential of PKM2 activators in MS-like disease and how these agents alter T cell function.
- 27 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (655)
Modulation of PKM activity affects the differentiation of T H 17 cells
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell–mediated autoimmunity that mimics multiple sclerosis (MS). TH17 cells are believed to orchestrate MS pathology, in part, through the production of two proinflammatory cytokines: interleukin-17 (IL-17) and GM-CSF. We found that both TEPP-46 and DASA-58 suppressed the development of IL-17–producing TH17 cells but increased the generation of those producing GM-CSF. This switch redirected disease pathology from the spinal cord to the brain. In addition, we found that activation of PKM2 interfered with TGF-β1 signaling, which is necessary for the development of TH17 and regulatory T cells. Collectively, our data clarify the therapeutic potential of PKM2 activators in MS-like disease and how these agents alter T cell function.